Pharma News

Researchers have identified how certain genes can contribute towards a person's susceptibility to stress fracture injuries, a fatigue-induced fracture of the bone caused by repeated pressure over time.

Eating a walnut-rich diet can be effective in losing weight and improving cholesterol level, finds a new study.

Patients with chronic obstructive pulmonary disease (COPD) demonstrate grey matter decreases in areas of the brain that process breathlessness, fear and sensitivity to pain, says a new study.

Collaboration and innovation is the key for healthcare and biotechnology companies to develop blockbuster drugs, said leading healthcare experts here on Tuesday.

Certain drugs currently used to treat diseases such as heart failure and cardiac arrhythmia have the potential to be effective in treatment of cancer, new research has found.

A common drug used by diabetes patients to prevent heart disease can be used to aid recovery from a heart attack, reveals a new study.

CTI BioPharma Corp. announced that the Company received written communication from the U.S. Food and Drug Administration (FDA) on February 4, 2016, that the FDA has placed a partial clinical hold on the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. This clinical hold impacts part of the clinical work currently being conducted under the IND and will also affect planned clinical trials.

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.

For the third quarter ended 31st December 2015, Zydus Cadila reported Total Operating Income of Rs. 2428 crores, up by 10% from Rs. 2205 crores in the corresponding quarter of the previous year on a consolidated basis. Net Profit for the same period was up by 38% from Rs. 282 crores to Rs. 390 crores.

[adsense:336x280:8701650588]